Molecular Templates Announces Start of Phase 1 Clinical Trial of MT-3724 in Refractory Non-Hodgkin’s Lymphoma Mar 05, 2015 8:00am EST
Molecular Templates Presents Preclinical Data on CD38-Targeted Engineered Toxin Body (ETB) at the American Association for Cancer Research Special Conference, Hematologic Malignancies: Translating Discoveries to Novel Therapies Sep 24, 2014 8:30am EDT
Molecular Templates Announces FDA Approval of Investigational New Drug Application for CD20 Internalizing Immunotoxin MT-3724 Sep 08, 2014 9:00am EDT
Molecular Templates Presents Preclinical Data on Engineered Toxin Bodies (ETBs) at the AACR Annual Meeting Apr 18, 2014 8:00am EDT
Molecular Templates Announces $8.5M Series C Financing and $10.6M Grant Funding Oct 08, 2013 8:00am EDT
Molecular Templates Announces RNAi Drug-Delivery Research Collaboration with Alnylam Pharmaceuticals May 04, 2011 9:00am EDT
Molecular Templates to Present Preclinical Data on Engineered Toxin Bodies (ETB) at the 5th Annual RNAi and miRNA World Congress Apr 22, 2011 9:00am EDT
Molecular Templates Announces Research Collaboration with Memorial Sloan-Kettering Cancer Center Apr 15, 2011 9:00am EDT
Molecular Templates to Present Preclinical Data on Engineered Toxin Bodies (ETB) at the AACR 102nd Annual Meeting Mar 30, 2011 4:18pm EDT
